Bispecific antibody and use thereof
AssigneeEarendil Labs Inc.
InventorsHao RAN, Jian HUANG, Zhenping ZHU, Jian PENG, Liang TIAN
Life of this patent
Estimating the term…
Abstract
The present application provides an isolated antigen-binding protein, comprising: a first binding domain and a second binding domain, wherein the first binding domain specifically binds to TNF-like protein A (TL1A), and the first binding domain and the second binding domain are different.
Claims30
1-36. (canceled)
An isolated antigen binding protein, comprising:
- a first binding domain and a second binding domain, wherein the first binding domain specifically binds to TNF-like protein A (TL1A), and the second binding domain specifically binds to IL-23p19, wherein the first binding domain comprises a heavy chain variable region (VH), and the VH comprises an HCDR3 comprising an amino acid sequence of SEQ ID NO:
- 14.
An isolated nucleic acid molecule encoding an antigen-binding protein comprising:
- a first binding domain and a second binding domain, wherein the first binding domain specifically binds to TNF-like protein A (TL1A), and the second binding domain specifically binds to IL-23p19, wherein the first binding domain comprises a heavy chain variable region (VH), and the VH comprises an HCDR3 comprising an amino acid sequence of SEQ ID NO:
- 14.
A method for preparing an isolated antigen-binding protein, comprising culturing a host cell comprising one or more nucleic acids encoding an isolated antigen binding protein, comprising a first binding domain and a second binding domain, wherein the first binding domain specifically binds to TNF-like protein A (TL1A), and the second binding domain specifically binds to IL-23p19, wherein the first binding domain comprises a heavy chain variable region (VH), and the VH comprises an HCDR3 comprising an amino acid sequence of SEQ ID NO:
- 14, and recovering the isolated antigen-binding protein.
A method for treating a TL1A or IL-23 mediated disease or condition in a subject in need thereof, the metho comprising:
- administering an isolated antigen binding protein to the subject, an antigen binding protein comprising a first binding domain and a second binding domain, wherein the first binding domain specifically binds to TNF-like protein A (TL1A), and the second binding domain specifically binds to IL-23p19, wherein the first binding domain comprises a heavy chain variable region (VH), and the VH comprises an HCDR3 comprising an amino acid sequence of SEQ ID NO:
- 14, thereby treating the subject.
Dependencies are inferred from the claim text.